Research ExplorerPublicationsImmunohistochemistry for Prostate Biopsy-Impact on Histologi...

Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making

Standard

Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. / Mandel, Philipp; Wenzel, Mike; Hoeh, Benedikt; Welte, Maria N; Preisser, Felix; Inam, Tahir; Wittler, Clarissa; Humke, Clara; Köllermann, Jens; Wild, Peter; Würnschimmel, Christoph; Tilki, Derya; Graefen, Markus; Kluth, Luis A; Karakiewicz, Pierre I; Chun, Felix K-H; Becker, Andreas.

In: CURR ONCOL, Vol. 28, No. 3, 09.06.2021, p. 2123-2133.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mandel, P, Wenzel, M, Hoeh, B, Welte, MN, Preisser, F, Inam, T, Wittler, C, Humke, C, Köllermann, J, Wild, P, Würnschimmel, C, Tilki, D, Graefen, M, Kluth, LA, Karakiewicz, PI, Chun, FK-H & Becker, A 2021, 'Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making', CURR ONCOL, vol. 28, no. 3, pp. 2123-2133. https://doi.org/10.3390/curroncol28030197

APA

Mandel, P., Wenzel, M., Hoeh, B., Welte, M. N., Preisser, F., Inam, T., Wittler, C., Humke, C., Köllermann, J., Wild, P., Würnschimmel, C., Tilki, D., Graefen, M., Kluth, L. A., Karakiewicz, P. I., Chun, F. K-H., & Becker, A. (2021). Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. CURR ONCOL, 28(3), 2123-2133. https://doi.org/10.3390/curroncol28030197

Vancouver

Mandel P, Wenzel M, Hoeh B, Welte MN, Preisser F, Inam T et al. Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making. CURR ONCOL. 2021 Jun 9;28(3):2123-2133. https://doi.org/10.3390/curroncol28030197

Bibtex

@article{09b9a8858a49478796bd9914f9d19acb,
title = "Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making",
abstract = "BACKGROUND: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making.METHODS: Between January 2017-June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy.RESULTS: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7-10.CONCLUSIONS: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.",
keywords = "Biopsy, Clinical Decision-Making, Humans, Immunohistochemistry, Male, Neoplasm Grading, Prostatic Neoplasms/diagnosis",
author = "Philipp Mandel and Mike Wenzel and Benedikt Hoeh and Welte, {Maria N} and Felix Preisser and Tahir Inam and Clarissa Wittler and Clara Humke and Jens K{\"o}llermann and Peter Wild and Christoph W{\"u}rnschimmel and Derya Tilki and Markus Graefen and Kluth, {Luis A} and Karakiewicz, {Pierre I} and Chun, {Felix K-H} and Andreas Becker",
year = "2021",
month = jun,
day = "9",
doi = "10.3390/curroncol28030197",
language = "English",
volume = "28",
pages = "2123--2133",
journal = "CURR ONCOL",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Immunohistochemistry for Prostate Biopsy-Impact on Histological Prostate Cancer Diagnoses and Clinical Decision Making

AU - Mandel, Philipp

AU - Wenzel, Mike

AU - Hoeh, Benedikt

AU - Welte, Maria N

AU - Preisser, Felix

AU - Inam, Tahir

AU - Wittler, Clarissa

AU - Humke, Clara

AU - Köllermann, Jens

AU - Wild, Peter

AU - Würnschimmel, Christoph

AU - Tilki, Derya

AU - Graefen, Markus

AU - Kluth, Luis A

AU - Karakiewicz, Pierre I

AU - Chun, Felix K-H

AU - Becker, Andreas

PY - 2021/6/9

Y1 - 2021/6/9

N2 - BACKGROUND: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making.METHODS: Between January 2017-June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy.RESULTS: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7-10.CONCLUSIONS: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.

AB - BACKGROUND: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making.METHODS: Between January 2017-June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy.RESULTS: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7-10.CONCLUSIONS: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.

KW - Biopsy

KW - Clinical Decision-Making

KW - Humans

KW - Immunohistochemistry

KW - Male

KW - Neoplasm Grading

KW - Prostatic Neoplasms/diagnosis

U2 - 10.3390/curroncol28030197

DO - 10.3390/curroncol28030197

M3 - SCORING: Journal article

C2 - 34207594

VL - 28

SP - 2123

EP - 2133

JO - CURR ONCOL

JF - CURR ONCOL

SN - 1198-0052

IS - 3

ER -